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What is going wrong in health research investment? post-pandemic 
lessons and the need for change
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   Abstract:  
 
The emergence of a new dimension of consciousness after the COVID-19 pandemic might provide an opportunity to 
highlight gaps and inequalities in health research investment and to mobilize scientific and public opinion to change the 
way things are done. This analysis considers some lessons learned from the pandemic crisis concerning the priority of 
global health research, research in prevention and well-being, and international research cooperation. The question 
raised by these issues concerns the un-fairness of health research funding, mainly dominated by the pharmaceutical 
and device industries. However, evidence shows that these companies shifted funding to late-phase clinical trials and 
away from innovation activity and global health priorities. On the other hand, public institutions continue to invest in 
basic science, with the majority of funds still focused on basic research and innovation. This direct relationship 
between industry and biomedical research disrupts the reliability of findings and biases the evidence. Several 
initiatives and efforts are shaping pathways towards health research independence from industry funding. We can 
propose the idea of industry funding without a direct relationship with researchers through a common pot managed by 
an independent international agency. Nevertheless, to promote publicly funded research, the scientific community 
must strengthen its position compared to industry-funded research through transparency and the scientific value of 
publications.   
 
  Keywords:  COVID-19, Post-pandemic, lessons, Tunisia 
 
Background  
Despite the difficult times during the COVID-19 crisis, people 
have hope and believe in the post-pandemic new world. It is a 
global awakening moment that reminds us that health and 
research remain as vital as ever. However, the failure to ensure 
against this pandemic is also a moment to consider health 
research's capacity to develop diagnostics, vaccines, and 
treatments to address global health issues and emergencies. The 
emergence of a new dimension of consciousness is perhaps an 
opportunity to identify and highlight gaps and inequalities in 
health research.  
 
What lessons can be learned from the COVID-19 pandemic 
for health research? 
1. Setting the priority of global health research 
Biomedical research has achieved remarkable success and 
advances with a significant worldwide impact on life 
expectancy and infectious diseases, such as poliomyelitis. 
However, several issues and questions must be raised. We 
should have seen this pandemic coming because we were 
warned long ago about the imminent risk of the emergence of a 
new coronavirus [1]. Why did this call, which should have 
required more investment, go unheeded? This is also the case 
for research projects on universal vaccines against the influenza 
virus, a major public health condition accounting for more than 
400,000 deaths worldwide each year [2]. Moreover, it should be 
recalled that we have long been waiting for effective results 
from research on the poor's infectious diseases. Globally, 4 
million people are infected with AIDS, 300 million with 
malaria, and 2 billion with tuberculosis [3]. 
     Each year, hundreds of billions of dollars are spent on health 
research, but only 5.0% is applied to what is commonly and 
truly known as "neglected tropical diseases" of low-income 
countries, where 93.0% of preventable deaths occur [4]. The 
first lesson learned from the COVID-19 pandemic is that 
diseases do not distinguish between borders, races, or rich and 
poor people. There is now a clear challenge for the global 
community and world leaders to focus on research on global 
public health needs. 
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2. Prevention and well-being  
The second lesson is the wide success of the promotion of basic 
preventive measures, such as hand-washing. It is now obvious 
that through the power of media and societal mobilization, we 
can take significant action to prevent many health issues. 
Imagine if we applied the same focus and sense of emergency 
to preventing road accidents or promoting healthy food and 
physical activity. To do so, we need more evidence to prove the 
impact of preventive measures on health and well-being. 
Currently, research investment is more focused on diseases and 
drugs than prevention and well-being. The problem begins with 
the World Health Organization's definition of health as 
"complete" well-being. This definition has been widely 
criticized because of the absoluteness of the word "complete," 
leaving most people unhealthy most of the time; this contributes 
to expanding the scope of the disease, health care technology, 
and drug industry [5]. The need for a new definition of health 
has been widely expressed. The best proposal is the concept of 
"health…as the ability to adapt and self-manage [6]. This new 
formulation could stimulate research on individuals' capacity to 
cope and adapt to their environment and limitations. In this 
regard, do not expect that the drug industry would invest in this 
nonprofit field of research. 
 
3. International research cooperation  
The global community understands that the only way to defeat 
the virus somewhere is to defeat it everywhere [7]. The "me 
first" approach embraced by some political and scientific 
leaders should be banished from the area of scientific research. 
This is another window of opportunity to highlight the crucial 
need for cross-border international scientific collaboration to 
develop global health solutions. It is time for researchers and 
policymakers to step forward to support global open access and 
the ongoing sharing of scientific information [8] and create a 
global space for more creativity and innovative ideas world-
wide. 
 
Why does it seem to go wrong? Health research funding, 
sources, and expenses?  
The above lessons learned from the COVID-19 crisis have 
revealed public opinion that health research seems to be taking 
the wrong track, missing global public health priorities due to a 
lack of international collaboration, and focusing more on drugs 
than prevention well-being. The question is why, and in what 
research are we investing? 
     In fact, it is all about money and the way it is spent on health 
research and development (R&D). Global investment is a 
difficult metric to obtain because of the diversity of funding 
sources. Public sources include government agencies, academic 
institutions, and charitable organizations, whereas industry 
sources include biotechnology, medical devices, and 
pharmaceutical firms. Chakra et al. reported in 2014 a global 
mapping of these funds according to regions and sources; in 
2012, the total amount spent on biomedical R&D reached 268.4 
billion US dollars, with an approximately 10.0% growth rate 
each year from 2007 to 2012 [8]. The US leads the amount of 
expenditure by far, and the largest contributor to R&D spending 
is an industry, with 64.0% of global funds (Fig.1) [9]. This 
supremacy of industry in biomedical research funding was also 
highlighted by Moses et al. [10] in their famous study on the 
"anatomy of medical research" in the US. The authors found 
that pharmaceutical companies shifted funding to late-phase 
clinical trials and away from innovation activity. These 
companies' investment in prehuman/preclinical activities ranges 
from 10.0% to 15.0%. On the other hand, public institutions 
continue to invest in basic science, with most funds still focused 
on basic research and innovation [10]. 
     Marcia Angell, former editor-in-chief of the New England 
Journal of Medicine, wrote a book in 2004 [11] denouncing 
what has come to be called "Big Pharma" the most profitable 
sector in the last decades, with more than 400 billion US dollars 
of sales in 2018 [12]. Angell noted several issues, such as 
favoring investment in producing more expensive "me-too 
drugs" that are merely variations of older drugs created to 
prolong patent rights, neglecting drugs for tropical diseases, and 
spending double on marketing what they spend on R&D, with 
all the ensuing conflict of interests’ issues. Furthermore, 
growing evidence indicates that industry is the most important 
driver of overdiagnosis through the promotion of minor 
"dysfunctions" labeled "custom-made diseases", leading to 
further tests and drugs [13]. This promotion can include the 
funding of patient and advocacy groups [14]. Consequently, 
"Big Pharma" has trapped biomedical research and taken 
control of evidence trends and priority setting. 
 
The evidence is biased as a consequence of industry 
influence  
A clinician is asked in daily practice to answer questions that 
matter to patients. Evidence-based medicine that combines the 
best research evidence with clinical expertise and patient values 
is the fundamental tool to make decisions. However, for many 
reasons, including bias, trustworthy evidence is becoming rare. 
The main bias often identified by authors is "sponsorship bias" 
[15,16], which may be the most trustworthy evidence that 
industry funding leads to more favorable efficacy results of a 
sponsor's products [17].  
     Furthermore, new evidence has identified sponsor 
involvement in the design and reporting of research [18]. There 
are major discrepancies between unpublished detailed clinical 
data and what is reported in medical journals [19] in some 
industry-funded studies. Recently, author participated as an 
investigator in a multicenter international prospective, double-
blind, randomized study comparing two drugs for the same 
problem. The study design and methodology seemed to be of a 
























Fig 1: 2012 Biomedical Research expenditures, by 
region and by public sector or private industry
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institution and a pharmaceutical company. However, author 
discovered the findings of the study has published in a 
prestigious medical journal, and they favor the sponsor's 
product. Moreover, the sponsor was cited at the end of the 
article as co-founder without specifying in what proportion. 
Author would has preferred this information to be clearly 
presented at the top of the article, with more precision on each 
funder's share. Author admits that he do not entirely trust these 
findings, because the direct relationship between industry and 
biomedical research disrupts the reliability of the findings. For-
profit companies and health research are two different entities 
with different ethics and may have contradictory goals, such as 
profit versus low-cost healthcare. 
 
Time to free health research from industry influence: some 
ideas to change the rules  
Several initiatives and efforts are shaping the pathways towards 
health research independence from industry funding. An 
example is the efforts of the British Medical Journal with 
influential researchers and advisers [15]. They have highlighted 
some successful models of either full public funding or models 
in-volving industry funding and public regulation, such as the 
Italian government, which has taxed drug companies to fund 
public interest research [20]. In the same vein, we proposed in 
2011 an idea involving industry funding without a direct 
relationship with researchers [21]. Companies and other stake-
holders (government, charitable organizations) would contribute 
to a common pot managed by an independent international 
agency. This agency would launch proposals for research 
projects to which re-searchers could respond to funding requests 
for projects developed by researchers worldwide. Projects 
would be accepted or rejected by an independent scientific 
committee. This system would involve no direct interaction 
between companies and researchers and preserve consistent 
industry financial support [21]. 
     On the other hand, to promote publicly funded research, the 
scientific community must strengthen its position compared to 
industry-funded research through transparency and the scientific 
value of publications. A strategy of transparency and a 
disclosure policy for conflicts of interests are important and 
necessary steps but remain insufficient to mitigate bias [22]. 
Other ideas can be proposed to favor and pro-mote independent 
research, such as the following: 
- Revisit the method of assessing the level of evidence of a 
published study by adding a weighting co-efficient that 
considers the funding of the study in favor of publicly-funded 
studies:  
▪ Revisit the evaluation of the notoriety of scientific 
journals. For example, for the impact factor that considers 
the average number of times that a journal is mentioned in 
recent articles published in a given year, we can propose 
the inclusion of only independent publications: - 
▪ Exclude industry-sponsored trials from systematic reviews 
and meta-analyses. 
British Medical Journal (BMJ), the Cochrane Foundation, and 
many other organizations have already begun to move in this di-
rection and advocate for independent research. The above ideas 
require further discussion to join a broad stream of research 
towards creating the groundwork for global cooperation for 
health research independence. 
How might the COVID-19 crisis be used to catalyze change?  
This hoped-for change requires a strong mobilization of 
scientific and public opinion to stand up to the power of Big 
Pharma. The COVID-19 crisis provides a new opportunity to 
popularize the problem, shed new light on the situation, and 
change the rules for funding and evaluating health research. 
With collective power and global awareness, a clear challenge 
is emerging. The global community, scientists, and 
policymakers must rebuild "healthy" health research:  
a. based on relevant and trustworthy findings, 
b. focused on global health needs, basic science, and well-
being, 
c. that is more innovative and open to global exchange. 
The main way to achieve this goal must be through health 
research's financial independence from industry influence. It is 
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